| 000 | 01487 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250514022236.0 | ||
| 264 | 0 | _c20020212 | |
| 008 | 200202s 0 0 fre d | ||
| 022 | _a0035-2640 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLarger, E | |
| 245 | 0 | 0 |
_a[Tissular toxicity of glucose and therapeutic perspectives]. _h[electronic resource] |
| 260 |
_bLa Revue du praticien _cOct 2001 |
||
| 300 |
_a1765-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAntioxidants _xtherapeutic use |
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xetiology |
| 650 | 0 | 4 |
_aDiabetic Retinopathy _xetiology |
| 650 | 0 | 4 |
_aEndothelium, Vascular _xcytology |
| 650 | 0 | 4 | _aFree Radicals |
| 650 | 0 | 4 |
_aFructose-Bisphosphate Aldolase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xanalysis |
| 650 | 0 | 4 | _aHemodynamics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperglycemia _xcomplications |
| 650 | 0 | 4 |
_aOxidoreductases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aProtein Kinase C _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aMarre, M | |
| 773 | 0 |
_tLa Revue du praticien _gvol. 51 _gno. 16 _gp. 1765-8 |
|
| 999 |
_c11706229 _d11706229 |
||